BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New GALDERMA R&D, Inc. International Research Facility


10/19/2005 5:09:36 PM

FT. WORTH, Texas, Jan. 6 /PRNewswire/ -- Galderma R&D, the worldwide research and development arm of Galderma Laboratories, based in Sophia-Antipolis, France, has begun construction of a revolutionary new research center that will have major implications for Galderma, L.P., in the United States.

The new facility, named "Funel" sits in the hills of Sophia-Antipolis, between the Alps and the Mediterranean. The dramatically different architecture of this facility is designed to promote and encourage creativity, ensuring a surge in innovation and innovative thinking. The facility will be home for over 500 employees, 280 of whom will be scientists.

Galderma's considerable investment in people, technology and new research facilities has already in the past two years produced five new chemical entities, which are entering pre-clinical and/or early development phases within two strategic therapeutic areas -- acne and psoriasis. The development of these chemical entities will largely impact Galderma's R&D center in the U.S. International's goal is to develop compounds globally and submit the dossiers simultaneously in the U.S. and Europe.

The impact in the United States is expected to be considerable as the new facility dedicates itself to being the global leader in dermatology. "We are very excited about this new R&D entity," commented Galderma L.P. president, Humberto C. Antunes. "More and more dermatology is becoming an exceedingly critical medical specialty. As the population ages and various skin diseases manifest themselves in greater numbers of people, we see the need for medicine that has a very real effect. There is no doubt that damage and disease brought about by exposure to the sun is a very present danger for many segments of the population and we need drugs and technologies that can help people live longer and healthier lives." The new "Funel" facility creates proximity between researchers and work-centers encouraging the flow of information. Its open spaces and transparent walls, which separate the lab spaces, allow for permanent visibility, encouraging curiosity and practical exchanges between complementary work centers. The facility will combine skills in up-to-date technologies such as genomics, proteomics, early pharmacokinetics and high throughput technologies such as screening -- chemistry and toxico-genomics.

Galderma is a worldwide dermatology company with United States headquarters in Ft. Worth, TX. Galderma manufactures and markets both prescription and over-the-counter dermatology products such as Differin(R) (adapalene) Cream, Gel, 0.1%, MetroGel(R) (metronidazole topical gel) Topical Gel, 0.75%, Tri-Luma(R) Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%), Rosanil(TM) (sodium sulfacetamide 10% and sulfur 5%) Cleanser, Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution, and Cetaphil(R) Cleansers and Moisturizers.

Galderma R&D

CONTACT: Suzanne Lane of Lane & Coady P.R., +1-212-757-6880,slane@lanecoadypr.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES